Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 15.45
(-3.44%)
SEK 15.45
(-3.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -35.05 Million SEK | -285.83% |
| 2022 | -9.08 Million SEK | 77.22% |
| 2021 | -39.87 Million SEK | -109.45% |
| 2020 | -19.03 Million SEK | 12.27% |
| 2019 | -21.7 Million SEK | -6988.03% |
| 2018 | 315.06 Thousand SEK | 102.36% |
| 2017 | -13.36 Million SEK | -115.31% |
| 2016 | -6.2 Million SEK | -268.19% |
| 2015 | -1.68 Million SEK | 69.48% |
| 2014 | -5.52 Million SEK | -6173.41% |
| 2013 | -88.03 Thousand SEK | -139.6% |
| 2012 | -36.74 Thousand SEK | 84.87% |
| 2011 | -242.76 Thousand SEK | 38.55% |
| 2010 | -395.08 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -26.55 Million SEK | 24.25% |
| 2024 Q2 | -15.52 Million SEK | 41.55% |
| 2023 Q3 | -35.32 Million SEK | -1971.07% |
| 2023 FY | -35.05 Million SEK | -285.83% |
| 2023 Q4 | -35.05 Million SEK | 0.78% |
| 2023 Q1 | -4.73 Million SEK | 47.92% |
| 2023 Q2 | 1.88 Million SEK | 139.91% |
| 2022 Q1 | -33.92 Million SEK | 14.93% |
| 2022 Q2 | -23.53 Million SEK | 30.62% |
| 2022 Q4 | -9.08 Million SEK | 57.66% |
| 2022 Q3 | -21.45 Million SEK | 8.84% |
| 2022 FY | -9.08 Million SEK | 77.22% |
| 2021 Q2 | -7.68 Million SEK | 46.63% |
| 2021 Q1 | -14.39 Million SEK | 24.4% |
| 2021 Q3 | -59.49 Million SEK | -674.44% |
| 2021 Q4 | -39.87 Million SEK | 32.97% |
| 2021 FY | -39.87 Million SEK | -109.45% |
| 2020 Q3 | -28.66 Million SEK | -135.75% |
| 2020 FY | -19.03 Million SEK | 12.27% |
| 2020 Q1 | -18.53 Million SEK | 14.61% |
| 2020 Q4 | -19.03 Million SEK | 33.58% |
| 2020 Q2 | -12.15 Million SEK | 34.39% |
| 2019 FY | -21.7 Million SEK | -6988.03% |
| 2019 Q1 | -39.73 Million SEK | -12711.67% |
| 2019 Q2 | -36.43 Million SEK | 8.3% |
| 2019 Q3 | -31.24 Million SEK | 14.24% |
| 2019 Q4 | -21.7 Million SEK | 30.55% |
| 2018 Q1 | -12.45 Million SEK | 6.8% |
| 2018 FY | 315.06 Thousand SEK | 102.36% |
| 2018 Q4 | 315.06 Thousand SEK | 104.28% |
| 2018 Q3 | -7.36 Million SEK | 30.97% |
| 2018 Q2 | -10.66 Million SEK | 14.36% |
| 2017 FY | -13.36 Million SEK | -115.31% |
| 2017 Q3 | -1.82 Million SEK | -1041.84% |
| 2017 Q4 | -13.36 Million SEK | -633.83% |
| 2017 Q2 | 193.32 Thousand SEK | 105.57% |
| 2017 Q1 | -3.46 Million SEK | 60.47% |
| 2016 Q2 | -9.54 Million SEK | 0.0% |
| 2016 Q4 | -8.77 Million SEK | 5.31% |
| 2016 FY | -6.2 Million SEK | -268.19% |
| 2016 Q3 | -9.26 Million SEK | 2.87% |
| 2015 Q2 | -3.96 Million SEK | 8.29% |
| 2015 FY | -1.68 Million SEK | 69.48% |
| 2015 Q4 | -1.68 Million SEK | 44.32% |
| 2015 Q3 | -3.02 Million SEK | 23.62% |
| 2015 Q1 | -4.32 Million SEK | 21.74% |
| 2014 Q4 | -5.52 Million SEK | 0.0% |
| 2014 FY | -5.52 Million SEK | -6173.41% |
| 2013 FY | -88.03 Thousand SEK | -139.6% |
| 2012 FY | -36.74 Thousand SEK | 84.87% |
| 2011 FY | -242.76 Thousand SEK | 38.55% |
| 2010 FY | -395.08 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 0.273% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.857% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 102.857% |
| Arcoma AB | -1.12 Million SEK | -3007.543% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 131.901% |
| BICO Group AB (publ) | 927.9 Million SEK | 103.778% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 127.215% |
| CellaVision AB (publ) | -56.94 Million SEK | 38.441% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -135.619% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -314.574% |
| C-Rad AB (publ) | -127.6 Million SEK | 72.529% |
| Duearity AB (publ) | 10.23 Million SEK | 442.616% |
| Dignitana AB (publ) | 13.07 Million SEK | 368.051% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 33.486% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.648% |
| Iconovo AB (publ) | -10.75 Million SEK | -225.913% |
| Integrum AB (publ) | -10.47 Million SEK | -234.587% |
| Luxbright AB (publ) | -13.83 Million SEK | -153.393% |
| Mentice AB (publ) | -49.56 Million SEK | 29.277% |
| OssDsign AB (publ) | -162.78 Million SEK | 78.467% |
| Paxman AB (publ) | -11.41 Million SEK | -207.187% |
| Promimic AB (publ) | -50.32 Million SEK | 30.344% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 283.813% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -28.287% |
| ScandiDos AB (publ) | -1.53 Million SEK | -2189.555% |
| Sectra AB (publ) | -772.85 Million SEK | 95.464% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 84.55% |
| Senzime AB (publ) | -139.54 Million SEK | 74.88% |
| SpectraCure AB (publ) | -50.23 Million SEK | 30.22% |
| Stille AB | -178.5 Million SEK | 80.363% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 102.854% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 83.67% |